Cargando…

Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer

OBJECTIVE: To investigate whether a radiomics model can help to improve the performance of PI-RADS v2.1 in prostate cancer (PCa). METHODS: This was a retrospective analysis of 203 patients with pathologically confirmed PCa or non-PCa between March 2015 and December 2016. Patients were divided into a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mou, Yang, Ling, Yue, Yufeng, Xu, Jingxu, Huang, Chencui, Song, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925826/
https://www.ncbi.nlm.nih.gov/pubmed/33680954
http://dx.doi.org/10.3389/fonc.2020.631831
_version_ 1783659335052689408
author Li, Mou
Yang, Ling
Yue, Yufeng
Xu, Jingxu
Huang, Chencui
Song, Bin
author_facet Li, Mou
Yang, Ling
Yue, Yufeng
Xu, Jingxu
Huang, Chencui
Song, Bin
author_sort Li, Mou
collection PubMed
description OBJECTIVE: To investigate whether a radiomics model can help to improve the performance of PI-RADS v2.1 in prostate cancer (PCa). METHODS: This was a retrospective analysis of 203 patients with pathologically confirmed PCa or non-PCa between March 2015 and December 2016. Patients were divided into a training set (n = 141) and a validation set (n = 62). The radiomics model (Rad-score) was developed based on multi-parametric MRI including T2 weighted imaging (T2WI), diffusion weighted imaging (DWI), apparent diffusion coefficient (ADC) imaging, and dynamic contrast enhanced (DCE) imaging. The combined model involving Rad-score and PI-RADS was compared with PI-RADS for the diagnosis of PCa by using the receiver operating characteristic curve (ROC) analysis. RESULTS: A total of 112 (55.2%) patients had PCa, and 91 (44.8%) patients had benign lesions. For PCa versus non-PCa, the Rad-score had a significantly higher area under the ROC curve (AUC) [0.979 (95% CI, 0.940–0.996)] than PI-RADS [0.905 (0.844–0.948), P = 0.002] in the training set. However, the AUC between them was insignificant in the validation set [0.861 (0.749–0.936) vs. 0.845 (0.731–0.924), P = 0.825]. When Rad-score was added to PI-RADS, the performance of the PI-RADS was significantly improved for the PCa diagnosis (AUC = 0.989, P < 0.001 for the training set and AUC = 0.931, P = 0.038 for the validation set). CONCLUSIONS: The radiomics based on multi-parametric MRI can help to improve the diagnostic performance of PI-RADS v2.1 in PCa.
format Online
Article
Text
id pubmed-7925826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79258262021-03-04 Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer Li, Mou Yang, Ling Yue, Yufeng Xu, Jingxu Huang, Chencui Song, Bin Front Oncol Oncology OBJECTIVE: To investigate whether a radiomics model can help to improve the performance of PI-RADS v2.1 in prostate cancer (PCa). METHODS: This was a retrospective analysis of 203 patients with pathologically confirmed PCa or non-PCa between March 2015 and December 2016. Patients were divided into a training set (n = 141) and a validation set (n = 62). The radiomics model (Rad-score) was developed based on multi-parametric MRI including T2 weighted imaging (T2WI), diffusion weighted imaging (DWI), apparent diffusion coefficient (ADC) imaging, and dynamic contrast enhanced (DCE) imaging. The combined model involving Rad-score and PI-RADS was compared with PI-RADS for the diagnosis of PCa by using the receiver operating characteristic curve (ROC) analysis. RESULTS: A total of 112 (55.2%) patients had PCa, and 91 (44.8%) patients had benign lesions. For PCa versus non-PCa, the Rad-score had a significantly higher area under the ROC curve (AUC) [0.979 (95% CI, 0.940–0.996)] than PI-RADS [0.905 (0.844–0.948), P = 0.002] in the training set. However, the AUC between them was insignificant in the validation set [0.861 (0.749–0.936) vs. 0.845 (0.731–0.924), P = 0.825]. When Rad-score was added to PI-RADS, the performance of the PI-RADS was significantly improved for the PCa diagnosis (AUC = 0.989, P < 0.001 for the training set and AUC = 0.931, P = 0.038 for the validation set). CONCLUSIONS: The radiomics based on multi-parametric MRI can help to improve the diagnostic performance of PI-RADS v2.1 in PCa. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7925826/ /pubmed/33680954 http://dx.doi.org/10.3389/fonc.2020.631831 Text en Copyright © 2021 Li, Yang, Yue, Xu, Huang and Song http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Mou
Yang, Ling
Yue, Yufeng
Xu, Jingxu
Huang, Chencui
Song, Bin
Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
title Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
title_full Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
title_fullStr Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
title_full_unstemmed Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
title_short Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
title_sort use of radiomics to improve diagnostic performance of pi-rads v2.1 in prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925826/
https://www.ncbi.nlm.nih.gov/pubmed/33680954
http://dx.doi.org/10.3389/fonc.2020.631831
work_keys_str_mv AT limou useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer
AT yangling useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer
AT yueyufeng useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer
AT xujingxu useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer
AT huangchencui useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer
AT songbin useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer